Public deck

AbCellera Biologics (ABCL) Coverage Bootstrap: cash-rich clinical-stage antibody platform with ABCL635 catalyst risk

Official-source baseline for AbCellera Biologics using SEC submissions, SEC company facts, the FY2025 10-K, Q1 FY2026 10-Q, filed Q1 2026 results, filed company presentations, and 2026 proxy materials.